The Thrombelastograph Hemostasis Analyzer (TEG) is used to monitor the properties of blood to determine and confirm that a patient's ability to clot is normal. If it is not, the TEG assists in making a diagnosis that shows the difference between a clotting problem or a bleeding problem and can guide a physician in the use of drug replacement therapy. Blood clotting is called hemostasis and is an active, extremely complex process, involving many interacting factors including clotting, fibrinolytic proteins, activators, inhibtors and cellular elements.
The TEG's approach is to monitor a patient's hemostasis using a small blood sample and documenting the interaction of platelets with the clotting cascade from the time of placing the blood sample in the device until the clot actually forms. The TEG measures the clot's physical properties to determine whether the patient will have normal hemostasis, will hemorrhage or will develop an inappropriate clot formation called thrombosis.
This instrument can reduce the need for transfusions during surgery by predicting how a patient's blood will clot. The TEG analyzes the platelets resistance or inhibition therby reducing drug intervention and blood product usage. Some reports have shown that by reducing exposure to blood, you reduce length of stay and mortality rates in high blood loss surgeries (i.e. open-heart surgery). The TEG can also accurately assess low molecular weight Heparin and Coumadin, and has the ability to distinguish surgical bleeding from non-surgical bleeding.
The TEG results are qualitative and quantitative, which means patient care can be altered and then improved in the following ways:
Improved patient outcomes
Reduced rate of re-operation
Prevention of strokes
Reduction in blood product usage
Decrease in cost by receiving multiple tests in one assay
Increase in patient safety by knowing the % of platelet inhibition
Results of test available within minutes
To learn more about the TEG visit: www.haemoscope.com